title: Targeting liver tumors by administering liposomal doxorubicin into the hepatic artery.
abstract: The plasma levels, organ distribution, and in vivo anti-tumor activity of liposomal doxorubicin administered i.v. or i.a. (hepatic) in rats bearing W256 liver tumors were studied. I.a. administration of liposomal doxorubicin resulted in 4-fold and 1.3-fold higher liver tumor and liver parenchyma doxorubicin levels, respectively, than i.v. administration, thus suggesting a more preferential distribution of liposomal doxorubicin into the liver tumor with i.a. administration. By contrast, the heart, spleen, and plasma AUCs were decreased 3.8-, 3.2-, and 16-fold, respectively, after i.a. administration. Cumulative urinary excretion at 8 hr was also 14 times lower in animals that received liposomal doxorubicin i.a. In good correlation with these findings, i.a. administration markedly enhanced the anti-tumor effect of liposomal doxorubicin against liver W256 tumors as measured by tumor growth inhibition 5 days after treatment (-16% for i.a. administration vs. +89% for i.v. administration, p less than or equal to 0.05) and prolongation of survival (ILS: 108% for i.a. administration vs. 26% for i.v. administration, p less than or equal to 0.05). Our results show that i.a. administration of liposomal doxorubicin results in preferential distribution of the anti-tumor agent into the tumor tissue and increased anti-tumor activity, while increasing the cardioprotective effect of the liposome carrier by decreasing the plasma peak and heart-tissue levels of the drug.
authors.affiliation: Pharmaceutical Research Institute, Shenyang College of Pharmacy, China.
authors.forename: Y
authors.initials: Y
authors.lastname: Zou
authors.forename: I
authors.initials: I
authors.lastname: Horikoshi
authors.forename: M
authors.initials: M
authors.lastname: Ueno
authors.forename: X
authors.initials: X
authors.lastname: Gu
authors.forename: R
authors.initials: R
authors.lastname: Perez-Soler
mesh_terms: D000818:Animals; D002279:Carcinoma 256, Walker / Q000098:blood supply / Q000188:drug therapy* / Q000378:metabolism; D004317:Doxorubicin / Q000008:administration & dosage* / Q000493:pharmacokinetics; D004337:Drug Carriers; D004339:Drug Compounding; D006499:Hepatic Artery; D007269:Injections, Intra-Arterial; D008081:Liposomes; D008099:Liver / Q000378:metabolism; D008113:Liver Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000378:metabolism; D009206:Myocardium / Q000378:metabolism; D051381:Rats; D014018:Tissue Distribution
chemical_list: D004337:Drug Carriers; D008081:Liposomes; D004317:Doxorubicin